Bezafibrate (Synonyms: BM15075)

Name: Bezafibrate
Brand: MedChemExpress
SKU: HY-B0637
Rating: 5.0 (13 reviews)

Cat. No.: HY-B0637 Purity: 99.83%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Bezafibrate is an agonist of PPAR, with EC₅₀s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

For research use only. We do not sell to patients.

CAS No. : 41859-67-0

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 13 publication(s) in Google Scholar

Other Forms of Bezafibrate:

13 Publications Citing Use of MCE Bezafibrate

Cell Imaging/Staining

In Vivo Efficacy Study

: Bezafibrate purchased from MedChemExpress. Usage Cited in: Nat Genet. 2025 Mar;57(3):680-693.; Western blot analysis of CPT1A and PD-L1 levels in cells treated with varying doses of Bezafibrate (BEZ).

: Bezafibrate purchased from MedChemExpress. Usage Cited in: Nat Genet. 2025 Mar;57(3):680-693.; Tumor growth of B16F10 cells in immune-normal mice was assessed by treatment with control group, BEZ (Bezafibrate: 15 mg/kg) group, anti-CTLA-4 group, or a combination of both.

: Bezafibrate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Apr 17:e2500272. [Abstract]; GFP‐specific fluorescence micrographs of HEK‐293T cells co‐transfected with (PGal4‐RXR,PPPARγ‐p65, P8UAS‐CMV) for 48 h in the presence or absence of 100 µM Bezafibrate.

: Bezafibrate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Apr 17:e2500272. [Abstract]; C57BL/6J mice were s.c. injected with HEK 293 cells encapsulated in sodium alginate into the right flank on day 0, followed by s.c immunized on day 7, 14 for three total vaccinations. Bezafibrate (10mg /kg) was administrated i.p. every three days. Anti‐tumor effects of bezafibrate‐triggered target gene expression were assessed.

: Bezafibrate purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2023 Dec 25;8(1):457. [Abstract]; U87 cells with high EGFRvIII density were cocultured with EGFRvIII-targeted CAR-T cells, supplemented with indicated drugs. Cells were magnetically separated for CAR molecule detection. Representative immunoblotting images from three independent duplications showed that Atorvastatin (5μM, 3 days) and Cytochalasin (10μg/mL, 1 day) alleviated CAR molecule transfer.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PPAR Isoform Specific Products:

View All Isoforms

PPARα PPARβ/δ PPARγ PPAR PPARδ

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

hPPARδ

20 μM (EC₅₀)

hPPARα

50 μM (EC₅₀)

hPPARγ

60 μM (EC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
CHO-K1	EC₅₀	> 137 μM Compound: Bezafibrate	Concentration of compound that affords half-maximum transactivation of human Peroxisome proliferator activated receptor gamma in CHO-K1 cells was determined in vitro Concentration of compound that affords half-maximum transactivation of human Peroxisome proliferator activated receptor gamma in CHO-K1 cells was determined in vitro	[PMID: 11738577]
CHO-K1	EC₅₀	> 143 μM Compound: bezafibrate	Agonist activity on Gal4 chimeric human Peroxisome proliferator activated receptor delta expressed in CHO-K1 cells Agonist activity on Gal4 chimeric human Peroxisome proliferator activated receptor delta expressed in CHO-K1 cells	[PMID: 12904063]
CHO-K1	EC₅₀	> 78 μM Compound: Bezafibrate	Transactivation of human Peroxisome proliferator activated receptor alpha expressed in CHO-K1 cells Transactivation of human Peroxisome proliferator activated receptor alpha expressed in CHO-K1 cells	[PMID: 11738577]
COS-7	EC₅₀	15.4 μM Compound: Bezafibrate	Agonist activity at Gal4-tagged human PPARgamma ligand binding domain expressed in COS-7 cells measured after overnight incubation by dual-glo luciferase reporter gene assay Agonist activity at Gal4-tagged human PPARgamma ligand binding domain expressed in COS-7 cells measured after overnight incubation by dual-glo luciferase reporter gene assay	10.1039/C6MD00042H
COS-7	EC₅₀	22.6 μM Compound: Bezafibrate	Agonist activity at Gal4-tagged human PPARdelta ligand binding domain expressed in COS-7 cells measured after overnight incubation by dual-glo luciferase reporter gene assay Agonist activity at Gal4-tagged human PPARdelta ligand binding domain expressed in COS-7 cells measured after overnight incubation by dual-glo luciferase reporter gene assay	10.1039/C6MD00042H
COS-7	EC₅₀	7.1 μM Compound: Bezafibrate	Agonist activity at Gal4-tagged human PPARalpha ligand binding domain expressed in COS-7 cells measured after overnight incubation by dual-glo luciferase reporter gene assay Agonist activity at Gal4-tagged human PPARalpha ligand binding domain expressed in COS-7 cells measured after overnight incubation by dual-glo luciferase reporter gene assay	10.1039/C6MD00042H
CV-1	EC₅₀	100 μM Compound: 2, benzafibrate	Agonist activity at human PPARgamma expressed in monkey CV1 cells by transactivation assay Agonist activity at human PPARgamma expressed in monkey CV1 cells by transactivation assay	[PMID: 18280733]
CV-1	EC₅₀	110 μM Compound: 3	Compound was tested for its agonist activity against murine Peroxisome proliferator activated receptor delta-GAL4 chimeric receptor in transfected CV-1 cells Compound was tested for its agonist activity against murine Peroxisome proliferator activated receptor delta-GAL4 chimeric receptor in transfected CV-1 cells	[PMID: 10508427]
CV-1	EC₅₀	20 μM Compound: 3	Compound was tested for agonist activity on human Peroxisome proliferator activated receptor delta-GAL4 chimeric receptor in transfected CV-1 cells Compound was tested for agonist activity on human Peroxisome proliferator activated receptor delta-GAL4 chimeric receptor in transfected CV-1 cells	[PMID: 10508427]
CV-1	EC₅₀	3 μM Compound: benzafibrate	Agonist activity at human PPARgamma expressed in CV1 cells by transactivation assay Agonist activity at human PPARgamma expressed in CV1 cells by transactivation assay	[PMID: 17964792]
CV-1	EC₅₀	30 μM Compound: 2, benzafibrate	Agonist activity at human PPARalpha expressed in monkey CV1 cells by transactivation assay Agonist activity at human PPARalpha expressed in monkey CV1 cells by transactivation assay	[PMID: 18280733]
CV-1	EC₅₀	30 μM Compound: 2, benzafibrate	Agonist activity at human PPARdelta expressed in monkey CV1 cells by transactivation assay Agonist activity at human PPARdelta expressed in monkey CV1 cells by transactivation assay	[PMID: 18280733]
CV-1	EC₅₀	30 μM Compound: benzafibrate	Agonist activity at human PPARalpha expressed in CV1 cells by transactivation assay Agonist activity at human PPARalpha expressed in CV1 cells by transactivation assay	[PMID: 17964792]
CV-1	EC₅₀	30 μM Compound: benzafibrate	Agonist activity at human PPARdelta expressed in CV1 cells by transactivation assay Agonist activity at human PPARdelta expressed in CV1 cells by transactivation assay	[PMID: 17964792]
CV-1	EC₅₀	50 μM Compound: 3	Compound was tested for agonist activity on human Peroxisome proliferator activated receptor alpha-Gal4 chimeric receptor in transfected CV-1 cells Compound was tested for agonist activity on human Peroxisome proliferator activated receptor alpha-Gal4 chimeric receptor in transfected CV-1 cells	[PMID: 10508427]
CV-1	EC₅₀	55 μM Compound: 3	Compound was tested for its agonist activity against murine Peroxisome proliferator activated receptor gamma-Gal4 chimeric receptor in transfected CV-1 cells Compound was tested for its agonist activity against murine Peroxisome proliferator activated receptor gamma-Gal4 chimeric receptor in transfected CV-1 cells	[PMID: 10508427]
CV-1	EC₅₀	60 μM Compound: 3	Compound was tested for agonist activity on human Peroxisome proliferator activated receptor gamma-Gal4 chimeric receptor in transfected CV-1 cells Compound was tested for agonist activity on human Peroxisome proliferator activated receptor gamma-Gal4 chimeric receptor in transfected CV-1 cells	[PMID: 10508427]
CV-1	EC₅₀	90 μM Compound: 3	Compound was tested for its agonist activity against murine Peroxisome proliferator activated receptor alpha-Gal4 chimeric receptor transfected CV-1 cells Compound was tested for its agonist activity against murine Peroxisome proliferator activated receptor alpha-Gal4 chimeric receptor transfected CV-1 cells	[PMID: 10508427]
HEK293	EC₅₀	35.74 μM Compound: 1	Agonist activity at human PPARdelta expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as activation of luciferase activity measured after 48 hrs by transactivation assay Agonist activity at human PPARdelta expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as activation of luciferase activity measured after 48 hrs by transactivation assay	[PMID: 23265844]
HEK293	EC₅₀	46.58 μM Compound: 1	Agonist activity at human PPARalpha expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as activation of luciferase activity measured after 48 hrs by transactivation assay Agonist activity at human PPARalpha expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as activation of luciferase activity measured after 48 hrs by transactivation assay	[PMID: 23265844]
HEK293	EC₅₀	70.36 μM Compound: 1	Agonist activity at human PPARgamma expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as activation of luciferase activity measured after 48 hrs by transactivation assay Agonist activity at human PPARgamma expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as activation of luciferase activity measured after 48 hrs by transactivation assay	[PMID: 23265844]
HepG2	EC₅₀	1.04 μM Compound: BZF	Transactivation of PPAR transfected in human HepG2 cells after 20 hrs by luciferase reporter gene assay Transactivation of PPAR transfected in human HepG2 cells after 20 hrs by luciferase reporter gene assay	[PMID: 23031596]
HepG2	EC₅₀	1.05 μM Compound: Benzafibrate	Transactivation of PPAR expressed in HepG2 cells after 20 hrs by luminescence assay Transactivation of PPAR expressed in HepG2 cells after 20 hrs by luminescence assay	[PMID: 22381047]
HepG2	EC₅₀	18.9 μM Compound: 1	Agonist activity at human PPARdelta expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity after 20 to 22 hrs by luciferase based transactivation assay Agonist activity at human PPARdelta expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity after 20 to 22 hrs by luciferase based transactivation assay	[PMID: 21215640]
HepG2	EC₅₀	42.5 μM Compound: 1	Agonist activity at human PPARalpha expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity after 20 to 22 hrs by luciferase based transactivation assay Agonist activity at human PPARalpha expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity after 20 to 22 hrs by luciferase based transactivation assay	[PMID: 21215640]
HepG2	EC₅₀	57.2 μM Compound: 1	Agonist activity at human PPARgamma expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity after 20 to 22 hrs by luciferase based transactivation assay Agonist activity at human PPARgamma expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity after 20 to 22 hrs by luciferase based transactivation assay	[PMID: 21215640]
INS1(832/13)	EC₅₀	6 nM Compound: 36	Induction of glucose-stimulated insulin secretion in rat INS-1 832/13 cells incubated for 5 mins by ELISA assay Induction of glucose-stimulated insulin secretion in rat INS-1 832/13 cells incubated for 5 mins by ELISA assay	[PMID: 33771587]
Sf21	IC₅₀	231.7 μM Compound: Bezafibrate	Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
Sf21	IC₅₀	391 μM Compound: Bezafibrate	Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]

In Vitro

Bezafibrate is an agonist of PPAR, with EC₅₀s of 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, and 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, respectively^[1].
Bezafibrate (> 200 μM) shows significant cytotoxicity against human retinal microvascular endothelial cells (HRMECs) and human retinal pigment epithelial ARPE-19 cells. Bezafibrate (30-100 μM) suppresses tumor necrosis factor (TNF)α induced inflammatory factors and regulates TNFα induced nuclear factor (NF)-κB transactivation in HRMEC. Bezafibrate inhibits VEGF-induced HRMECs migration, and inhibits interleukin (IL)-1β-induced VEGF secretion of ARPE-19 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Bezafibrate (0.5%) markedly reduces plasma lipid and glucose levels, and increases islet area in the pancreas in TallyHo mice. Bezafibrate also improves energy expenditure and metabolic flexibility. Moreover, Bezafibrate ameliorates steatosis, modifies lipid composition and increases mitochondrial mass in the liver^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

361.82

Formula

C₁₉H₂₀ClNO₄

CAS No.

41859-67-0

Appearance

Solid

Color

White to off-white

SMILES

CC(C)(OC1=CC=C(CCNC(C2=CC=C(Cl)C=C2)=O)C=C1)C(O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvent & Solubility

In Vitro:

DMSO : ≥ 50 mg/mL (138.19 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.7638 mL	13.8190 mL	27.6381 mL
5 mM	0.5528 mL	2.7638 mL	5.5276 mL
10 mM	0.2764 mL	1.3819 mL	2.7638 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.91 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.91 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.83%

Select Batch:

Data Sheet (276 KB) SDS (392 KB)

COA (245 KB) HNMR (247 KB) RP-HPLC (251 KB) LCMS (94 KB)

Handling Instructions (2659 KB)

References

[1]. Willson TM, et al. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000 Feb 24;43(4):527-50. [Content Brief]

[2]. Usui-Ouchi A, et al. The peroxisome proliferator-activated receptor pan-agonist bezafibrate suppresses microvascular inflammatory responses of retinal endothelial cells and vascular endothelial growth factor production in retinal pigmented epithelial cells. Int Immunopharmacol. 2017 Nov;52:70-76. [Content Brief]

[3]. Franko A, et al. Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice. Mol Metab. 2017 Jan 6;6(3):256-266. [Content Brief]

Cell Assay ^[2]	Cell viability is assessed using the CCK-8 kit. Hhuman retinal microvascular endothelial cells (HRMECs) or ARPE-19 cells are seeded at 5000 cells/well in medium containing 10% serum in 96-well plates. After a 24-h incubation, the medium is serum-starved with 1% FBS for 6 h, the CCK-8 reagent is added, and the absorbance of the resultant solution is measured at 450 nm by using a microplate reader at three time points, 24, 48, and 72 h after treatment with Bezafibrate (0, 10, 50, 100, 200, 500, and 1000 μM)^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[3]	TallyHo mice are bred in our animal facility. Only male mice are used in the study, and mice receive a standard diet (SD), which is supplemented with 0.5% (w/w) Bezafibrate for the Bezafibrate groups for 8 weeks. Animals are killed by isoflurane overdose, and dissected tissues are prepared as stated below. All data represent samples taken after 8 weeks of Bezafibrate (or SD) treatment unless otherwise stated^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Willson TM, et al. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000 Feb 24;43(4):527-50. [Content Brief] [2]. Usui-Ouchi A, et al. The peroxisome proliferator-activated receptor pan-agonist bezafibrate suppresses microvascular inflammatory responses of retinal endothelial cells and vascular endothelial growth factor production in retinal pigmented epithelial cells. Int Immunopharmacol. 2017 Nov;52:70-76. [Content Brief] [3]. Franko A, et al. Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice. Mol Metab. 2017 Jan 6;6(3):256-266. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.7638 mL	13.8190 mL	27.6381 mL	69.0951 mL
	5 mM	0.5528 mL	2.7638 mL	5.5276 mL	13.8190 mL
	10 mM	0.2764 mL	1.3819 mL	2.7638 mL	6.9095 mL
	15 mM	0.1843 mL	0.9213 mL	1.8425 mL	4.6063 mL
	20 mM	0.1382 mL	0.6910 mL	1.3819 mL	3.4548 mL
	25 mM	0.1106 mL	0.5528 mL	1.1055 mL	2.7638 mL
	30 mM	0.0921 mL	0.4606 mL	0.9213 mL	2.3032 mL
	40 mM	0.0691 mL	0.3455 mL	0.6910 mL	1.7274 mL
	50 mM	0.0553 mL	0.2764 mL	0.5528 mL	1.3819 mL
	60 mM	0.0461 mL	0.2303 mL	0.4606 mL	1.1516 mL
	80 mM	0.0345 mL	0.1727 mL	0.3455 mL	0.8637 mL
	100 mM	0.0276 mL	0.1382 mL	0.2764 mL	0.6910 mL

Bezafibrate Related Classifications

Metabolic Disease Cardiovascular Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Bezafibrate41859-67-0BM15075BM 15075BM-15075PPARPeroxisome proliferator-activated receptorsInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Bezafibrate (Synonyms: BM15075)

Customer Review

Other Forms of Bezafibrate:

Bezafibrate Related Antibodies

13 Publications Citing Use of MCE Bezafibrate

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PPAR Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Bezafibrate Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Bezafibrate Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report